Lindbrook Capital, LLC Castle Biosciences Inc Transaction History
Lindbrook Capital, LLC
- $1.06 Billion
- Q2 2024
A detailed history of Lindbrook Capital, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Lindbrook Capital, LLC holds 172 shares of CSTL stock, worth $4,905. This represents 0.0% of its overall portfolio holdings.
Number of Shares
172
Previous 172
-0.0%
Holding current value
$4,905
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CSTL
# of Institutions
171Shares Held
25.5MCall Options Held
511KPut Options Held
130K-
Black Rock Inc. New York, NY3.04MShares$86.8 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.33MShares$66.4 Million0.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$45 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.5MShares$42.7 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.22MShares$34.7 Million0.44% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $750M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...